Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer

Abstract

This study suggests that both tumor differentiation and tumor size is the most important clinical predicator of pathologic tumor response, it may be of benefit in the selection of treatment options in locally advanced gastric cancer.

Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer

“…To date, several studies have investigated efficient predictive markers for treatment response. One study reported that tumor differentiation and tumor size could be used as a clinical predicator of pathologic tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer [26]. Gene methylation status was also reported as a predicator of chemotherapy response in gastric cancer [27,28].…”

Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction

“…51 A study come from China also suggested that both tumor size and tumor differentiation is the most important clinical predicator of pathologic tumor response. 52 Studies have indicated that lymph nodal status remains one of the most prognostic factors in patients with resected gastric cancer. 53,54 Therefore, the insufficient lymph node dissection for the node-positive cases increases the potential risk of postoperative cancer recurrence.…”

Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer

“…In line with this, it has been perceived that responders have a significantly better outcome since 1999[23]. Despite the fact that only a limited number of studies presented conflicting result[20][24][25], this conception was further confirmed by several subsequent studies[26][27][28][29]. Taken together, tumor response to NAC could be served as an independent prognostic factor for better prognosis (Figure 2).…”

“…Another study suggested TNM staging, histological type, tumor location, sex and age were correlated with histopathological response[27], however, the tumor regression related factors were not fully investigated in this study. Our previous retrospective study of 108 LAGC patients revealed that both tumor size and tumor differentiation were independent predictive marker for NAC responders, who were with better overall survival[28]. Interestingly, based on our updated database, a hypothesis-generating study found serum low-density lipoprotein measurement is useful in predicting chemosensitivity, higher low-density lipoprotein is statistically significant with histopathological response in LAGC patients undergoing NAC[42].…”

“…[26] modified Mandard's regression score to make it more adaptable to gastric cancer. Specifically, according to Becker's scoring system, histopathological responders are defined as patients with less than 10% residual tumor cells after NAC[28][34]. While another study proposed that only patients without residual tumor cells(complete tumor regression) could be considered to be histopathological responders[35].…”